Navigation Links
Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development
Date:11/4/2010

Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development -- LYON, France, November 4, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Infection Control, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development

 

LYON, France, November 4, 2010 /PRNewswire-FirstCall/ --

- First Phase 3 Study Underway in Australia

Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia.

This study is part of a global phase 3 clinical study program aimed at advancing the development of a novel vaccine for the prevention of dengue disease in children and adults. Currently, there is no specific treatment available for dengue fever, which is a threat to nearly three billion people and a public health priority in many countries of Latin America and Asia where epidemics occur.(3)

Phase 3 studies are the ultimate steps in the clinical development of a vaccine before it is submitted to regulatory authorities for evaluation for market authorization. Sanofi Pasteur's candidate dengue vaccine is the first to reach phase 3 of clinical development.

"To address the global health challenge represented by dengue fever, we are conducting an unprecedented dengue vaccine research and development program as well as a scale up of the vaccine production," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "We are now entering the final laps of a long run that Sanofi Pasteur started almost 20 years ago. If successful, we are committed to introducing the vaccine in countries where dengue is of highest public health priority."

The study in Australia is the first to use dengue vaccine doses produced with industrial scale processes. The study is aimed at demonstrating that production of the vaccine at industrial scale will meet consistency criteria required for market authorization by regulatory authorities. Details of the phase 3 study in Australia as well as results of already completed studies are presented at the 59th annual conference of ASTMH (American Society of Tropical Medicine and Hygiene), held in Atlanta (Georgia, United States), November 3-7.

Sanofi Pasteur's global dengue vaccine clinical study program

Sanofi Pasteur's candidate dengue vaccine-which targets all four virus serotypes-has been evaluated in clinical studies (Phase 1, 2) in adults and children in the U.S., Asia and Latin America. Overall, a balanced immune response against all four serotypes was observed after three doses of the vaccine. The vaccine is well tolerated with a similar safety profile after each dose.(4)

Clinical studies in adults and children are ongoing in Mexico, Colombia, Honduras, Puerto Rico, Peru, the Philippines, Vietnam, Singapore, Australia, and Thailand.

About dengue fever

Dengue fever is a mosquito-borne disease caused by four dengue virus serotypes (1 to 4). Overall, the disease is a potential threat to almost half of the world's population. Of the estimated 220 million people infected annually, two million-mostly children-develop dengue hemorrhagic fever (DHF), a severe form of the disease.(5) DHF is a leading cause of hospitalization, placing tremendous pressure on strained medical resources and having a heavy economic and societal impact. Many factors have contributed to the re-emergence and dramatic increase in dengue fever including urbanization and increased travel which facilitates dissemination of dengue viruses and the circulation of all four dengue virus serotypes.

For continuous up to date information about dengue fever outbreaks, visit http://www.denguewatch.org, a news hub reporting worldwide alerts on dengue, provided by the Pediatric Dengue Vaccine Initiative.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: http://www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us

1. Dengue vaccine efficacy trials in progress, http://www.thelancet.com/infection, vol 9, November 2009

2. Jean Lang, Recent progress on Sanofi Pasteur's dengue vaccine candidate. Journal of Clinical Virology 46, S2 (2009) 20-24

3. WHO Fact sheet No117, March 2009 Dengue and dengue haemorrhagic fever

4. Saville et al, Clinical development of a tetravalent dengue vaccine for endemic areas, ICID Miami, March 2010; Lang et al, Toward a tetravalent dengue vaccine in Brazil, Tropical Medicine meeting, Iguacu Falls, March 2010

5. PDVI Newsletter No 7, April 2010 accessible at http://www.pdvi.org/PDVI_newsletter/newsletter.asp

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

http://www.sanofipasteur.us

http://www.sanofipasteur.com


'/>"/>
SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... F ast access to ... at the point of need   ... and services, has launched a ClinicalKey mobile app that enables ... Elsevier designed the mobile app to allow users to select access to ... Android and iOS formats for mobile phone and tablet. ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists ... cell-isolation method that opens the door to genetic ... now have been impossible to isolate with 100 ... isolate specific tumor types in various stages of ... variants of these cells that are clinically relevant, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March ... Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center in ... for both the condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its Third ... February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event ... the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization ...
(Date:2/11/2016)... ... February 11, 2016 , ... The book, “Computers Should ... services, what questions to ask your IT consultant before signing a contract and how ... computer network. , “With companies relying heavily on e-mail and technology, it’s more important ...
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of ... Round Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian ... Billy Cundiff. , “We are honored to support a promising young investigator from Dr. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
Breaking Medicine News(10 mins):